Human fibrinogen concentrate - LFB Biomedicaments

Drug Profile

Human fibrinogen concentrate - LFB Biomedicaments

Alternative Names: Clottafact; FGTW; FibCLOT; Fibrinogen - LFB Biomedicaments

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Innsbruck Medical University; LFB Biomedicaments
  • Developer LFB Biomedicaments
  • Class Acute-phase proteins; Antihaemorrhagics; Blood coagulation factors; Blood proteins; Coagulants
  • Mechanism of Action Fibrinogen replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Afibrinogenaemia; Blood coagulation disorders

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Coagulation-disorders(In the elderly, In adults) in Denmark (IV, Powder)
  • 21 Mar 2017 Registered for Afibrinogenaemia in Austria, Belgium, Czech Republic, Spain, Slovakia, Slovenia, Norway, Netherlands, Luxembourg, Italy, Finland, Greece (IV)
  • 24 Aug 2016 No recent reports on development identified - Preregistration for Coagulation disorders in Turkey (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top